All of the above findings suggest that intestinal microecological regulators have great potential to improve the outcome of established therapies in RA patients, especially prebiotics in improving symptom severity and probiotics may have a promising role in upregulating inflammatory markers such as CRP and IL-1β. This evidence concerns the gene CRP and rheumatoid arthritis.